Surrey Heartlands

Joint Formulary & PAD

Ticagrelor - Prevention of atherothrombotic events - Acute Coronary Syndrome

You are here : Home > Formulary Search > Ticagrelor - Prevention of atherothrombotic events - Acute Coronary Syndrome

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
NICE
Restrictions / Comments :
 

Status 2

Blue
Formulations :
  • Oro-dispersible
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
NICE
Restrictions / Comments :
Important
Reserve for use in patients with swallowing difficulties.

Documentation

Guidelines (Local)
Dual antiplatelet-anticoagulant therapy - Aide memoire for managing Hospital Requests
Shared Care
Ticagrelor BLUE information sheet Feb17
Shared Care
Ticagrelor in ACS - Blue information sheet (SASH) - February 2017
Shared Care
GWCCG/RSCH Ticagrelor in ACS - Blue information sheet - February 2017

PAD Profile

ChemicalSubstance :
Ticagrelor
Indication :
Prevention of atherothrombotic events - Acute Coronary Syndrome
Group Name :
Keywords :
ACS, dual antiplatelet therapy, triple antiplatelet therapy, DAPT
Brand Names Include :
Brilique
Important Information :
Clopidogrel is the preferred option. Specialist initiation and at least one month supply before transfer to primary care
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
4
Traffic Light Entries :
2

Other Indications

Below are listed other indications that Ticagrelor is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Prevention of atherothrombotic events - Acute Coronary Syndrome.

Committee Recommendations (2)

29 Jul 20 - Surrey Heartlands Medicines Safety Committee (MSC)

Co-prescribing of antiplatelets / anticoagulants may be requested by a specialist in a number of scenarios.

The Medicines safety Group have produced an aide memoire to list the information that must be available to the primary care clinican  to support the safe prescribing of dual / triple therapies in primary care.

See below for document: "Dual antiplatelet-anticoagulant therapy - Aide memoire for managing hospital requests"

01 Feb 17 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
A scheduled review of the expired information sheet has taken place and was approved at PCN. The place in therapy of antiplatelets in Acute Coronary Syndrome had previously been discussed by the PCN in January 2013 and the policy statement from those discussions still stands. See below for approved BLUE information sheet and policy statement (PCN 42-2013) from previous discussions.